Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 525.87 mg (equivalent: cefalexin, qty 500 mg) - capsule - excipient ingredients: lactose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; brilliant blue fcf; quinoline yellow; purified water; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 52.6 mg/ml (equivalent: cefalexin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 26.3 mg/ml (equivalent: cefalexin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: sodium lauryl sulfate; allura red ac; methylcellulose; dimeticone 350; xanthan gum; pregelatinised maize starch; sucrose; flavour - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 52.576 mg/ml (equivalent: cefalexin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; simethicone; iron oxide yellow; citric acid; sucrose; saccharin sodium; guar galactomannan; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 26.288 mg/ml (equivalent: cefalexin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sodium benzoate; guar galactomannan; iron oxide yellow; saccharin sodium; citric acid; simethicone; sucrose; flavour - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cefalexin monohydrate, quantity: 525.76 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; gelatin; purified water; titanium dioxide - treatment of the following infections when caused by susceptible strains of the designated microorganisms. respiratory tract infections. caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis. caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and skin structure infections. caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis. caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 526 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; quinoline yellow; gelatin; magnesium stearate; patent blue v; dimeticone 350; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 263 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; dimeticone 350; magnesium stearate; titanium dioxide; patent blue v; quinoline yellow; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ertapenem sodium, quantity: 1.046 g (equivalent: ertapenem, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate; sodium hydroxide; nitrogen - treatment,ertapenem juno is indicated for the treatment of patients, aged 3 months or more, with moderate to severe infections (except meningitis, see precautions) caused by susceptible strains of microorganisms which are suspected or proven to be resistant to all other antibiotics, or for patients unable to tolerate other antibiotics.,ertapenem juno is also indicated for initial empiric therapy for the treatment of complicated intra-abdominal infections and acute pelvic infections including post-partum endomyometritis, septic abortion and post-surgical gynaecological infections.,ertapenem juno is also indicated for the treatment of diabetic foot infections, which require parenteral antibiotic therapy and are caused by susceptible bacterial pathogens which are suspected or proven to be resistant to all other registered antibiotics, or for patients unable to tolerate other antibiotics. ,appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to ertapenem. therapy with ertapenem juno may be initiated empirically before the results of these tests are known; once these results become available, antimicrobial therapy,should be adjusted accordingly.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefalotin sodium, quantity: 1.058 g (equivalent: cefalotin, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate - indications: cephalothin sodium for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. culture and susceptibility studies should be performed. however, therapy may be instituted before results of susceptibility studies are obtained (see pharmacology: microbiology). respiratory tract: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, klebsiella, and h. influenzae. skin and soft tissue: infections, including peritonitis, caused by staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, e.coli, pr. mirabilis and klebsiella. genitourinary tract: infections caused by e. coli, pr. mirabilis and klebsiella. septicaemia, including endocarditis: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, s. viridans, e. coli, pr. mirabilis and klebsiella. bone and joint: infection caused by staphylococci (penicillinase and non-penicillinase producing). prophylactically in vaginal hysterectomy, head and neck surgery, insertion of prosthetic heart valves, and prosthetic arthroplasty. cephalothin is not recommended for gastrointestinal procedures or other sites where anaerobic organisms such as bacteriodes tend to prevail. dosage is required pre-, intra-and postoperatively (i.e perioperatively, see dosage and administration). if signs of postoperative infection develop, specimens should be cultured to identify the causative organism so that appropriate therapy can be instituted. note: if the susceptibility tests show that the causative organism is resistant to cephalothin, other appropriate antibiotic therapy should be instituted.